论文部分内容阅读
目的探讨孟鲁司特钠治疗小儿咳嗽变异性哮喘的临床疗效。方法将100例咳嗽变异性哮喘患儿随机分为治疗组和对照组,每组各50例,治疗组予以孟鲁司特及沙丁胺醇气雾剂治疗,对照组予以辅舒酮、沙丁胺醇气雾剂治疗;比较两组患儿的近期疗效、症状缓解时间和复发率。结果治疗组的有效率为90%,明显高于对照组的56%,两组比较差异有统计学意义(χ2=19.441,P=0.001)。治疗组哮喘症状缓解时间为(5.9±2.6)d,而对照组为(8.0±3.2)d,两组比较差异有统计学意义。治疗结束6个月后,治疗组复发率为12%(6/50),对照组复发率为38%(19/50),两组比较差异有统计学意义(χ2=9.013,P=0.003)。结论孟鲁司特钠治疗小儿咳嗽变异性哮喘疗效确切,有效性高,复发率低,安全性好,值得临床推广。
Objective To investigate the clinical efficacy of montelukast sodium in the treatment of children with cough variant asthma. Methods 100 cases of cough variant asthma children were randomly divided into treatment group and control group, each group of 50 cases, the treatment group to montelukast and salbutamol aerosol treatment, the control group to be given ketone, salbutamol aerosol Treatment; compare the two groups of children’s short-term efficacy, symptom relief time and recurrence rate. Results The effective rate of the treatment group was 90%, which was significantly higher than that of the control group (56%). There was significant difference between the two groups (χ2 = 19.441, P = 0.001). The relief time of asthma in the treatment group was (5.9 ± 2.6) d, while it was (8.0 ± 3.2) days in the control group. The differences between the two groups were statistically significant. Six months after the end of treatment, the recurrence rate was 12% (6/50) in the treatment group and 38% (19/50) in the control group, with significant difference between the two groups (χ2 = 9.013, P = 0.003) . Conclusion Montelukast sodium treatment of pediatric cough variant asthma with effective, high efficiency, low recurrence rate, good safety, worthy of clinical promotion.